Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROBE2: Rilpivirine + Darunavir/Cobicistat in Virologically Suppressed HIV Patients
NCT04064632Phase 4Unknown
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- Feb 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rilpivirine, darunavir, cobicistat in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Papa Giovanni XXIII Hospital. Status: unknown.
02
Drugs
rilpivirinedarunavircobicistat
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04064632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04064632.